ADVERTISEMENT
  • News
  • Technology
  • Culture
  • Entertainment
  • Sport
  • Travel
  • Music
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Monday, December 4, 2023
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
Home Business Pharmacy

US US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack

The FINANCIAL by The FINANCIAL
September 4, 2015
in Pharmacy
Reading Time: 2 mins read
A A
0
Share on FacebookShare on Twitter

The FINANCIAL — AstraZeneca on September 3 announced that the US Food and Drug Administration (FDA) has approved BRILINTA (ticagrelor) tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year. With this expanded indication, BRILINTA is now approved to reduce the rate of cardiovascular death, myocardial infarction (MI, also known as heart attack) and stroke in patients with acute coronary syndrome (ACS) or a history of MI.

BRILINTA is an oral antiplatelet treatment that works by inhibiting platelet activation and was first approved by the FDA in July 2011 on the basis of data from the PLATO study. For at least the first 12 months following ACS, it is superior to clopidogrel and is the first and only oral antiplatelet to demonstrate superior reductions in cardiovascular death. BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. In the management of ACS, the recommended maintenance dose of BRILINTA is 90mg twice daily during the first year after the ACS event. After one year, patients with a history of heart attack can now be treated with 60mg twice daily, according to AstraZeneca.

Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development, AstraZeneca, said: “We know that patients remain at risk beyond the first year after their heart attack. Today’s approval is an important milestone that underscores the role BRILINTA can play in reducing the risk of a subsequent cardiovascular event for patients both in the acute setting and in the longer term.”

RelatedPosts

Roche ranked the most sustainable healthcare company in the DJSI

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

The expanded indication for BRILINTA has been approved under FDA Priority Review, a designation granted to medicines that the FDA determines have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease. The approval is based on the PEGASUS TIMI-54 study1, a large-scale outcomes trial involving more than 21,000 patients. PEGASUS TIMI-54 investigated ticagrelor tablets plus low-dose aspirin, compared to placebo plus low dose aspirin, for the long-term prevention of cardiovascular death, heart attack and stroke in patients who had experienced a heart attack one to three years prior to study enrollment.

Marc Sabatine, MD, MPH, Chairman, Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women’s Hospital, Boston, MA, USA and lead investigator for PEGASUS-TIMI 54, said: “The PEGASUS-TIMI 54 trial demonstrated that the addition of ticagrelor to low-aspirin in patients with a prior heart attack significantly reduces the risk of dying from cardiovascular causes, having another heart attack, or having a stroke. While it’s important that physicians tailor their treatment approach for each patient, these data speak to the clinically important benefit that can be gained when adding ticagrelor to the current standard therapy in a patient population at increased risk for recurrent cardiovascular events in the long-term.”

BRILINTA has been approved in over 100 countries and is included in 12 major ACS treatment guidelines globally. In the American Heart Association (AHA)/American College of Cardiology (ACC) 2014 NSTE-ACS Guideline, BRILINTA is preferred over clopidogrel for the maintenance treatment in NSTE-ACS patients (Class IIa) and is recommended as a treatment option in the management of NSTE-ACS patients (Class I).

The new BRILINTA 60mg tablet is expected to be available in pharmacies by the end of September 2015.

 

ADVERTISEMENT
The FINANCIAL

The FINANCIAL

Related Posts

Roche ranked the most sustainable healthcare company in the DJSI
Pharmacy

Roche ranked the most sustainable healthcare company in the DJSI

by The FINANCIAL
November 16, 2020
0

The FINANCIAL -- For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index...

Read more
Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

November 16, 2020
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

November 12, 2020
Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

November 12, 2020
ADVERTISEMENT
  • Trending
  • Comments
  • Latest
Jeff Schwartz on Emergence and Evolution of Private Debt Markets

Jeff Schwartz on Emergence and Evolution of Private Debt Markets

October 18, 2023
mobile-banking.jpg

The experts at Symple Lending discuss how rising interest rates are make paying down credit cards more difficult.

September 6, 2023
Subway® and Wissol Group Partner to Expand Subway’s Presence in Georgia

Subway® and Wissol Group Partner to Expand Subway’s Presence in Georgia

November 8, 2023
EasyJet to fly to London from Stockholm Arlanda

The London Diplomatic List, Addresses, Contacts & Working Hours

January 23, 2023
Tegeta Holding won two nominations in the Corporate Sustainability Award Competition

Tegeta Holding won two nominations in the Corporate Sustainability Award Competition

October 23, 2023
Decline in HIV transmission in in UK but progress slow in women

Decline in HIV transmission in in UK but progress slow in women

December 3, 2023
Agriculture & forestry energy consumption stable

Agriculture & forestry energy consumption stable

December 3, 2023
FAO: “Milk Production in Georgia is an Attractive Niche for Investing In” 

Which regions are focused on cereals and milk production?

December 3, 2023
Tourism peak months differ across EU regions

Tourism peak months differ across EU regions

December 3, 2023
EU expenditure on R&D reaches €352 billion in 2022 Eurostat

EU expenditure on R&D reaches €352 billion in 2022 Eurostat

December 3, 2023

Popular Last 24h

  • The Washington State revokes, suspends licenses ანდ registrations of health care providers

    The Washington State revokes, suspends licenses ანდ registrations of health care providers

    90 shares
    Share 36 Tweet 23
  • Ukraine: Easing of offensive on Avdiivka shows Russian’s ‘running out of steam’

    66 shares
    Share 26 Tweet 17
  • A man has died and two others injured, including a British man on a street in central Paris.

    19 shares
    Share 8 Tweet 5
  • England players rocked by earthquake in Antigua ahead of ODI series

    17 shares
    Share 7 Tweet 4
  • Jeff Schwartz on Emergence and Evolution of Private Debt Markets

    625 shares
    Share 250 Tweet 156
  • Read Jürgen Klopp’s Fulham programme notes in full

    12 shares
    Share 5 Tweet 3
  • EU expenditure on R&D reaches €352 billion in 2022 Eurostat

    12 shares
    Share 5 Tweet 3

LATEST POSTS

Decline in HIV transmission in in UK but progress slow in women

Decline in HIV transmission in in UK but progress slow in women

December 3, 2023
Agriculture & forestry energy consumption stable

Agriculture & forestry energy consumption stable

December 3, 2023
FAO: “Milk Production in Georgia is an Attractive Niche for Investing In” 

Which regions are focused on cereals and milk production?

December 3, 2023
Tourism peak months differ across EU regions

Tourism peak months differ across EU regions

December 3, 2023
EU expenditure on R&D reaches €352 billion in 2022 Eurostat

EU expenditure on R&D reaches €352 billion in 2022 Eurostat

December 3, 2023
The Washington State revokes, suspends licenses ანდ registrations of health care providers

The Washington State revokes, suspends licenses ანდ registrations of health care providers

December 3, 2023
Ukraine: Easing of offensive on Avdiivka shows Russian’s ‘running out of steam’

Ukraine: Easing of offensive on Avdiivka shows Russian’s ‘running out of steam’

December 3, 2023
A man has died and two others injured, including a British man on a street in central Paris.

A man has died and two others injured, including a British man on a street in central Paris.

December 3, 2023
England players rocked by earthquake in Antigua ahead of ODI series

England players rocked by earthquake in Antigua ahead of ODI series

December 3, 2023
Read Jürgen Klopp’s Fulham programme notes in full

Read Jürgen Klopp’s Fulham programme notes in full

December 3, 2023

LATEST INTERVIEWS

Lighting the path for sustainability in Georgia

Lighting the path for sustainability in Georgia

by The FINANCIAL
August 14, 2023
0

Toyota Plays a Crucial Role in Contributing to Georgia’s Zero Emissions Challenge

Toyota Plays a Crucial Role in Contributing to Georgia’s Zero Emissions Challenge

by The FINANCIAL
July 12, 2023
0

“EU membership might attract European banks and other financial institutions to enter Georgia”

“EU membership might attract European banks and other financial institutions to enter Georgia”

by The FINANCIAL
May 15, 2023
0

Main risks facing banks in 2023

Main risks facing banks in 2023

by The FINANCIAL
May 15, 2023
0

‘Russia cannot be treated as a reasonable and reliable trade partner

‘Russia cannot be treated as a reasonable and reliable trade partner

by The FINANCIAL
February 13, 2023
0

We should increase our joint efforts to assist the growing tech sector here in Georgia

We should increase our joint efforts to assist the growing tech sector here in Georgia

by The FINANCIAL
February 13, 2023
0

‘Georgia has much to offer to UK investors

‘Georgia has much to offer to UK investors

by The FINANCIAL
February 13, 2023
0

‘The best way for the Georgian economy to prosper is to join the EU

‘The best way for the Georgian economy to prosper is to join the EU

by The FINANCIAL
February 13, 2023
0

Newsletter

ADVERTISEMENT

GET IN TOUCH

E-mail your company news at:

news (at) financial.ge Letters to the Editor: editor (at) finchannel.com

Local Marketing contact:

(+99532) 2252 275 | 76 EXT: 1 (+995 558) 03 03 03 (mobile) marketing (at) finchannel.com

Requests from abroad:

(+99532) 2252 275 | 76 EXT: 7 (+995599) 96 52 52 Email: zviadi (@) finchannel.com Contact video editor: E-mail: video (at) financial.ge

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.